Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

Key Points

• To evaluate the long-term outcomes of durvalumab following chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.
• Analysis of mature data from the PACIFIC-R cohort
• Focus on overall survival (OS) and real-world progression-free survival (rwPFS)
• Assessment of durvalumab as a consolidation therapy
• Durvalumab shows improved overall survival in the cohort
• Real-world progression-free survival supports effective treatment outcomes
• Findings advocate for durvalumab as standard of care in this patient population